Danaher Corporation (DHR) fair value analysis
S&P 500 · Updated 2026-10-19
DHR price how computed
Forward Fair Value verdict
Fairly valuedDHR is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $219.81
- Sector
- Healthcare
- 12-month range
- $161.91–$242.05
- Market cap
- $155B
- From 52-week high
- -9.2%
- Shares outstanding
- 703M
- Rank in Healthcare by discount to fair value
- #55 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Danaher Corporation is a diversified conglomerate that operates through multiple segments providing products and services in life sciences, diagnostics, environmental and applied solutions, and dental products. The company operates globally across numerous countries and serves customers in research, clinical, environmental, and industrial markets worldwide.
DHR currently ranks #55 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 6 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $155B
- P/E (trailing)
- 27x
- Revenue (TTM)
- $25.1B
- Net margin
- 15.9%
- EPS (TTM)
- $8.12
- Gross margin
- 57.6%
- Debt / equity
- 0.51
- Revenue growth (3-yr avg)
- 3.8%
- Shares outstanding
- 703M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Contracting
- 52-week position
- The upper-middle quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 64 · neutral
- 50-day average
- $213.90
- 200-day average
- $201.32
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Dividends how computed
- Paid, last 12 months
- $1.52 per share (4 payments)
- Yield on last price
- 0.69%
- Consecutive years of increases
- 1
- Last ex-dividend date
- 2026-09-30
- Last payment date
- 2026-10-30
Earnings how computed
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+5.4%)
2026-03 ▲ beat (+6.2%)
2025-12 ▲ beat (+1.8%)
2025-09 ▲ beat (+9.9%)
2025-06 ▲ beat (+9.8%)
2025-03 ▲ beat (+14.6%)
2024-12 ▼ miss (-0.9%)
2024-09 ▲ beat (+8.9%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 22 buy · 3 hold · 0 sell (25 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $241
- Target vs last price
- +9.6%
What our data shows for DHR
- Our model validated 17 trailing price-to-earnings windows for DHR, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $161.91–$242.05.
- The 14-day relative strength index sits at a neutral 64.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for DHR
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent DHR news
TickrTrends' derived news-sentiment signal for DHR is currently leaning positive, computed from recent coverage.
- Danaher Corp (DHR) Reports Q3 2026 Earnings, Highlights Growth Strategy and Strong Execution (gurufocus.com, 2026-10-21)
TickrTrends take: Danaher's Q3 2026 earnings report and articulation of its growth strategy come at a time when TickrTrends indicates the company trades at fair value, suggesting the market has already priced in much of its execution capability. For investors focused on valuation, the key question is whether management's highlighted growth initiatives can deliver results that either justify the current fair valuation or potentially create upside if execution exceeds expectations. Given DHR's position in the healthcare sector, the strength of its operational performance relative to guidance will be critical in determining whether the fairly valued assessment shifts in either direction. - Danaher Corporation (DHR) Q3 2026 Earnings Call Transcript (seekingalpha.com, 2026-10-21)
TickrTrends take: Danaher Corporation operates in the Healthcare sector and is currently assessed as fairly valued according to TickrTrends metrics. With Q3 2026 earnings now available for review, investors focused on valuation should examine whether the company's reported results and forward guidance support the fairly valued designation or signal potential shifts in the underlying fundamentals that drive that assessment. The earnings call transcript provides detailed commentary on operational performance and management's outlook that can inform whether current valuation levels remain appropriately calibrated to the company's prospects. - Q3 2026 Danaher Corporation Earnings Call Transcript (gurufocus.com, 2026-10-21)
TickrTrends take: Danaher Corporation's Q3 2026 earnings results provide an opportunity to assess whether the company's operational performance supports its current fairly valued status in the Healthcare sector. For valuation-focused investors, key metrics to monitor include revenue growth trajectory, margin expansion or contraction, and cash generation relative to the company's current valuation multiples. Any significant divergence between earnings growth and the market's pricing could indicate whether the fairly valued designation remains appropriate going forward.
More DHR news
- Danaher’s Stock Is Pricing in a Recovery. Can Its Earnings Deliver? (insidermonkey.com, 2026-10-16)
- Danaher (DHR) Partners with Nvidia to Accelerate AI-Driven Scientific Discovery (gurufocus.com, 2026-10-14)
- Danaher (DHR) Expands Board to 13 Members, Appoints Daniel Comas and Dr. Robert Hershberg (gurufocus.com, 2026-10-13)
- Danaher Has Barely Moved in a Year. Is its 25x Earnings Valuation Justified? (insidermonkey.com, 2026-10-05)
- Danaher Corp Names Julie Sawyer Montgomery as CEO, Stock Trades Slightly Below GF Value™ (gurufocus.com, 2026-10-01)
What people are saying
Follow the DHR conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — DHR's sector discount rank improved this week, moving from number 69 to number 64 among Healthcare sector companies. The stock maintains a Fairly valued assessment based on TickrTrends' derived indicators.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for DHR show a shift in valuation positioning this week. The sector discount rank declined from 56 to 62, indicating the stock's relative valuation advantage within the Healthcare sector has narrowed. The valuation verdict moved from Undervalued to Fairly valued, reflecting the change in how DHR's current metrics compare to its peer group.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is DHR stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), DHR is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is DHR's TickrTrends verdict?
DHR's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does DHR compare to other Healthcare stocks?
DHR ranks #55 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is DHR overbought or oversold?
DHR's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does DHR pay a dividend?
Yes. DHR paid $1.52 per share over the last twelve months (4 payments), a 0.69% yield on TickrTrends' last price, and has raised the annual total for 1 consecutive year. The last ex-dividend date was 2026-09-30.
Does DHR usually beat earnings estimates?
Over its last 8 reported quarters DHR beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about DHR?
Of 25 analysts covering DHR, 22 rate it a buy, 3 a hold and 0 a sell - buy-leaning, with a consensus price target of $241 (+9.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
DHR vs ACHC · DHR vs COR · DHR vs CVS · DHR vs HCA · DHR vs IQV